Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SRZN vs NBP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NBP Captures Overall Composite Edge (51.9 HOLD vs 32.8 SELL), While SRZN Leads 3–2 on Growth & Valuation Pillars

NBP Overall Winner 6-Pillar Tally: SRZN 3 – 2 NBP (1 Tie) Matrix Metrics: SRZN 4 – 5 NBP

As of Nov 16, 2026, NBP (NBP) captures the overall head-to-head institutional edge over Surrozen, Inc. Common (SRZN) on higher Unified Composite conviction (51.9/100 HOLD vs. 32.8/100 SELL) after splitting the core matrix 5–4 (led by Valuation Multiples, Profitability & Quality), while SRZN wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $32.80 (N/M Forward P/E, -485.4% operating margin) versus NBP at $0.79 (2.7x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: NBP earns the overall head-to-head edge with a stronger Unified Composite Score (51.9/100 HOLD vs. SRZN 32.8/100 SELL) and 1.66β · 81% Vol risk profile, whereas SRZN leads top-line expansion (+408.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 62.9); meanwhile NBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs NBP
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.80
+3.76% 1D
Market Cap $603.7M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.21β · 62% Vol
Unified Composite Score
32.8 / 100 SELL
Tech 50.0 Fund 32.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.1% over 20 days), RSI 63
RSI-14: 62.9 · SMA20: $29.54 · SMA50: $26.11
NBP US Equity Head-to-Head Winner
NBP
Institutional Equity
$0.79
-6.66% 1D
Market Cap $96.3M
TTM Revenue N/A
Forward P/E 2.7x
Beta / 30D Vol 1.66β · 81% Vol
Unified Composite Score
51.9 / 100 HOLD
Tech 60.0 Fund 50.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.4%), weak momentum, RSI 20
RSI-14: 20.1 · SMA20: $1.08 · SMA50: $1.31

6-Pillar Scorecard Institutional Category Breakdown (SRZN 3 – 2 NBP)

Columns: Metric · SRZN · NBP
1. Valuation Multiples NBP
Forward P/E N/M 2.7x
Trailing P/E N/M 2.7x
PEG Ratio N/M N/M
EV / Revenue 48.4x N/M
2. Growth & Scale SRZN
Revenue Growth (YoY) +408.6% +0.0%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $11M N/A
Market Cap $603.7M $96.3M
3. Profitability & Quality NBP
Gross Margin N/A N/A
Operating Margin -485.4% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.8% -59.1%
4. Balance Sheet & Cash Flow SRZN
Cash Generation (TTM) -$31M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $95M Net Cash $1.73 Book/Sh · -59.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.0% (5th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (4) vs NBP (5)
Institutional Metric SRZN NBP Criterion Row Edge
Market Capitalization
Scale
$603.7M $96.3M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M 2.7x Lower Multiple NBP
Forward P/E Ratio
Valuation
N/M 2.7x Lower Multiple NBP
Revenue Growth (YoY)
Growth
+408.6% +0.0% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-485.4% 0.0% Higher Margin NBP
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.8% -59.1% Higher ROE NBP
52-Week Range Position
Momentum
80% ($12–$38) 0% ($1–$5) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.21β · 62% Vol 1.66β · 81% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
32.8 / 100 (SELL) 51.9 / 100 (HOLD) Higher Composite NBP
Trailing 12M Revenue (USD)
Operating Scale
$11M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 48.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) N/A ($1.73 Book/Sh · -59.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +76.97 pp
SRZN: +39.93% · NBP: -37.04%
3M Horizon SRZN +94.7 pp
SRZN: +36.67% · NBP: -58.03%
6M Horizon SRZN +73.14 pp
SRZN: +19.53% · NBP: -53.61%
1Y Horizon SRZN +251.61 pp
SRZN: +170.63% · NBP: -80.98%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRZN vs NBP. Trailing 12-month operating profitability (SRZN -485.4% vs NBP 0.0%) and valuation multiples (SRZN N/M vs NBP 2.7x Forward P/E) are benchmarked directly in Pillar 4 below.

SRZN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin-485.4%
ROE / Fwd P/E-62.8% · N/M
NBP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-59.1% · 2.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
37d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NBP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $603.7M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NBP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $96.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs NBP Key Questions & Quantitative Answers

As of Nov 16, 2026, NBP (NBP) captures the overall head-to-head institutional edge over Surrozen, Inc. Common (SRZN) on higher Unified Composite conviction (51.9/100 HOLD vs. 32.8/100 SELL) after splitting the core matrix 5–4 (led by Valuation Multiples, Profitability & Quality), while SRZN wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $32.80 (N/M Forward P/E, -485.4% operating margin) versus NBP at $0.79 (2.7x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: NBP earns the overall head-to-head edge with a stronger Unified Composite Score (51.9/100 HOLD vs. SRZN 32.8/100 SELL) and 1.66β · 81% Vol risk profile, whereas SRZN leads top-line expansion (+408.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: SRZN trades in a Markup technical trend (CONSOLIDATION options phase, RSI 62.9); meanwhile NBP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 20.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with NBP at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SRZN generates $11M in USD-normalized revenue versus N/A for NBP. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NBP.

NBP screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.4x EV/Revenue (unreported FCF margin), whereas NBP trades at 2.7x Forward P/E, 2.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus NBP (-59.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 62% Vol realized risk). By comparison, NBP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.66β · 81% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.